Cell therapy is broader than stem cells
Cell therapy uses living cells as part of a medical intervention. Depending on the product and indication, cells may replace damaged tissue, modify an immune response, deliver a biological function or support repair. Not every cell therapy uses stem cells, and not every laboratory cell technology is available to patients.
Examples across medicine include hematopoietic stem-cell transplantation, immune-cell therapies, mesenchymal stromal cell products and organ-specific progenitor-cell approaches. These technologies differ substantially in manufacturing, evidence, risk and regulation.
Autologous and allogeneic pathways
Autologous therapies use the patient’s own cells. They may require a collection procedure, central manufacturing, release testing and a later treatment visit. Allogeneic products use donor-derived cells and may be manufactured in batches. The correct pathway depends on the product rather than on marketing language.
| Question | Autologous | Allogeneic |
|---|---|---|
| Source | The patient | A screened donor |
| Timing | Collection and processing may add time | Product may be prepared in advance |
| Key review | Collection suitability and manufacturing | Donor screening, compatibility and product consistency |
| Evidence | Must be specific to the exact product and indication | |
Manufacturing and quality questions
For cell therapy, manufacturing is part of the treatment. Identity, purity, viability, sterility, potency, transport conditions and release criteria can affect safety and consistency. Patients do not need to become laboratory experts, but they should know which medical institution and manufacturing entity are responsible.
Why organ-specific pathways deserve separate review
An organ-specific progenitor-cell programme for lung disease should not be evaluated as if it were the same as a generic intravenous MSC offer. The tissue source, mechanism, route, imaging requirements and clinical endpoints may be different. This is why our treatment pages are organised around defined conditions and pathways.
Access for international patients
Even when a cell-therapy pathway exists in China, foreign-patient access may depend on passport status, the ability to complete follow-up, language support, local testing and whether the institution currently accepts overseas cases. We verify these practical conditions separately.